Milestone Pharmaceuticals (MIST) Net Income towards Common Stockholders: 2021-2022
Historic Net Income towards Common Stockholders for Milestone Pharmaceuticals (MIST) over the last 1 years, with Sep 2022 value amounting to -$14.6 million.
- Milestone Pharmaceuticals' Net Income towards Common Stockholders fell 2.33% to -$14.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$58.2 million, marking a year-over-year change of. This contributed to the annual value of -$42.9 million for FY2021, which is 14.24% up from last year.
- Latest data reveals that Milestone Pharmaceuticals reported Net Income towards Common Stockholders of -$14.6 million as of Q3 2022, which was up 13.79% from -$16.9 million recorded in Q4 2021.
- Over the past 5 years, Milestone Pharmaceuticals' Net Income towards Common Stockholders peaked at -$12.5 million during Q2 2021, and registered a low of -$16.9 million during Q4 2021.
- For the 2-year period, Milestone Pharmaceuticals' Net Income towards Common Stockholders averaged around -$14.5 million, with its median value being -$14.4 million (2021).
- Data for Milestone Pharmaceuticals' Net Income towards Common Stockholders shows a maximum YoY dropped of 2.33% (in 2022) over the last 5 years.
- Milestone Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$16.9 million in 2021, then fell by 2.33% to -$14.6 million in 2022.
- Its last three reported values are -$14.6 million in Q3 2022, -$16.9 million for Q4 2021, and -$14.2 million during Q3 2021.